Stem Cell Manufacturing Market by Product (Stem Cell Lines [Hematopoietic stem cells (HSC), Mesenchymal stem cells (MSC), Induced Pluripotent Stem cells (iPSC), Embryonic stem cells (ESC), Neural Stem cells (NSC), and Multipotent adult progenitor stem cells], Instruments [Bioreactors and Incubators, Cell Sorters, and Others], and Consumables [Culture Media and Others]), Application (Research Applications, Clinical Applications, and Cell and Tissue Banking), and End User (Pharmaceutical and Biotechnology Companies, Hospitals and Surgical Centers, Academic Institutes and Research Laboratories, and Cell and Tissue Banks): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026455 | Pages: 100 | Industry: Biotechnology | Date: Sep 2022 | Type: Global

The market crossed the US$ 11.69 billion mark in 2022 and is expected to hit US$ 23.89 billion by 2030, recording a CAGR of 9.3% during the forecast period.

Increasing investments in stem cell-based research, led to significant growth of the market.

Stem cells play a crucial role in providing effective disease management and specialized research initiatives, such as genomic testing and personalized medicine. Stem cell research holds promise for generating breakthroughs against various conditions, including cancer, diabetes, heart disease, Alzheimer’s, and even COVID-19. In 2004, the California Institute for Regenerative Medicine (CIRM) was launched with US$ 3 billion in funding approved by the state’s voters. In the 16 years since (till 2020), CIRM has funded various stem cell research throughout California, promoting basic science and development of numerous potential therapies. In addition, in May 2022, Canada’s Stem Cell Network (SCN) invested US$ 19.5 million for 32 stem cell and regenerative medicine research projects and clinical trials. The investment by the network, became the largest funding injection into the sector in last 20-year history. With the support from 34 partner organizations valued at US$ 22.4 million, Canada’s regenerative medicine research community can harness a total of US$ 42 million for research activities and clinical trials over the next three years. Therefore, various public and private stakeholders worldwide are increasingly investing in the development of stem cell-based technologies which is driving the growth if the market in the forecast period. The consumables segment is expected to pace up owing to frequent purchase of consumables, growing stem cell research, and rising demand for these therapies.

Within the report, the market is subsegmented into product, application, end user, and geography. By product, the market is segmented into stem cell lines, instruments, and consumables. On the basis of stem cell lines, the market is subsegmented into hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), induced pluripotent stem cells (iPSC), embryonic stem cells (ESC), neural stem cells (NSC), and multipotent adult progenitor stem cells. On the basis of instruments, the market is sub segmented into bioreactors and incubators, cell sorters, and others. On the basis of consumables, the market is segmented into culture media and others. Based on application, the market is categorized into research applications, clinical applications, and cell and tissue banking. By end user, the market is categorized into pharmaceutical and biotechnology companies, hospitals and surgical centers, academic institutes and research laboratories, cell and tissue banks. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Increasing usage of personalized medicines and development of new therapies are fueling the growth of the market.

Within the rapidly growing stem cell market, stem cell manufacturing focuses on the technologies that enable the current laboratory-based practice of stem cell tissue culture to be transferred to the clinic as therapeutics while maintaining product and process control, automation, reproducibility, validation, and safety. Moreover, the rising popularity of personalized medicines is also propelling the market growth. New procurement methods are discovered by researchers to be applied for developing personalized medicines. For instance, iPSC therapies are developed by using small samples from a patient’s blood or skin cell that is later reprogrammed to develop new cells and tissue for transplant. Thus, with the application of these cells, potential personalized medicines can be produced. In addition, companies are focusing on the development of new therapies for reducing stress associated with COVID-19. In October 2020, Novellus Therapeutics Limited and NoveCite entered into a partnership for developing & commercializing NoveCite iPSCs for treating COVID-19-associated acute respiratory distress syndrome (ARDS).

Rising clinical trials across the research sector are accelerating the market growth.

The research segment dominated the market in 2022 owing to the rising focus on stem cell cytology & pathophysiology research and growing public-private funding to support stem cell product development and commercialization. Moreover, according to clinicaltrials.gov, in the US, there were about 1,803 registered recruiting and non-recruiting clinical trials across different phases of development related to stem cell therapy for different indications as of February 2022. The trials across the different stages showed positive outcomes, augmenting the market's growth in the future.

Recent strategic developments in stem cell manufacturing market

The stem cell manufacturing market has undergone several significant developments, and a few of these have been mentioned below:

  • In October 2019, Thermo Fisher Scientific launched Gibco BenchStable Media, the latest offering in the Gibco product line that provide a flexible alternative for biological researchers and also saves energy. It remains stable at room temperature and reduces reliance on cold storage.
  • In September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell. These services make it easier for pluripotent stem cell researchers to achieve critical yet often overlooked steps.
  • In September 2021, LifeCell International Pvt. Ltd received an investment of US$ 27.8 (INR 225) crore from OrbiMed Asia Partners IV in return for a minority stake, enabling the company to make a foray into adjacent new categories, such as fertility health and cell-based therapeutics.

The stem cell manufacturing market is driven by several players by implementing strategic activities such as investments, product launches, mergers & acquisitions, and partnerships. Thermo Fisher Scientific; Merck KGaA; Lonza Group AG; Takara Bio Inc.; STEMCELL Technologies Inc.; NuVasive, Inc.; and Becton, Dickinson, and Company are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Stem cell banks
  • Associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • Biotechnology companies
  • Cell-based research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented based on:

  • Product:
    • Stem Cell Lines
      • Hematopoietic stem cells (HSC)
      • Mesenchymal stem cells (MSC)
      • Induced Pluripotent Stem cells (iPSC)
      • Embryonic stem cells (ESC)
      • Neural Stem cells (NSC)
      • Multipotent adult progenitor stem cells
    • Instruments
      • Bioreactors and Incubators
      • Cell Sorters
      • Others
    • Consumables
      • Culture Media
      • Others
  • Application:
    • Research Applications
    • Clinical Applications
    • Cell and Tissue Banking
  • End User:
    • Pharmaceutical and Biotechnology Companies
    • Hospitals and Surgical Centers
    • Academic Institutes and Research Laboratories
    • Cell and Tissue Banks
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Thermo Fisher Scientific
    • Merck KGaA
    • Lonza Group AG
    • Takara Bio Inc.
    • STEMCELL Technologies Inc.
    • NuVasive, Inc.
    • Becton, Dickinson, and Company
    • Miltenyi Biotec
    • Holostem Terapie Avanzate
    • Sartorius AG.

Companies profiled
- Thermo Fisher Scientific
- Merck KGaA
- Lonza Group AG
- Takara Bio Inc.
- STEMCELL Technologies Inc.
- NuVasive, Inc.
- Becton, Dickinson, and Company
- Miltenyi Biotec
- Holostem Terapie Avanzate
- Sartorius AG.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000